Aspirin reduces risk of gastrointestinal cancer

At the 25th European gastroenterological week (Barcelona, Spain), the results of the unprecedented study on the aspirin influence on the oncological pathology development, in particular on malignant neoplasms of the gastrointestinal tract, revealed that aspirin can prevent the oncological process, especially in the elderly.

As far as is known, the incidence rate of digestive cancer (colorectal cancer, stomach cancer, liver cancer, pancreatic cancer, esophageal cancer, intestinal cancer) is quite high. In addition, oncological diseases of the gastrointestinal tract are very insidious and are leading in the mortality statistics among cancer diseases.

In modern days, experts are focusing more and more on the cancer prevention, and in this regard, the US Preventive Services Task Force recommends “initiating low-dose aspirin use for the primary prevention of [colorectal cancer] in adults aged 50 to 59 […] willing to take low-dose aspirin daily for at least 10 years.”

The basis for the modified recommendations was the following studies. Prof. Kelvin Tsoi from the Chinese University of Hong Kong and his colleagues conducted an extensive study over a period of 10 years, including 600,000 participants, aimed at studying the preventive effect of aspirin intake on the development of gastrointestinal cancer.

206,295 participants aged averagely 67,5 years took aspirin during approx. 7.7 years at a dose of 80 mg. The authors of the study report: “Long-term aspirin use reduces the risk of digestive cancer development by 24-47%.” Respectively, risk of the liver and esophagus cancer decreased by 47%, gastric cancer -38%, and pancreatic cancer – 34% . Moreover, the risk of developing colorectal cancer was lowered by 24%.

It was also reported that the long-term aspirin use also reduces the risk of leukemia, lung cancer and prostate cancer, but, unfortunately, is not effective for such malignant pathologies cancer as: breast, bladder, kidney, multiple myeloma.